Table 2 Non-serious adverse events during erlotinib treatment
Adverse event | Number of patients (%) | Number of events |
|---|---|---|
Rash | 36 (58.1%) | 43 |
Diarrhoea | 17 (27.4%) | 26 |
Dry skin | 11 (17.7%) | 15 |
Pruritus | 9 (14.5%) | 10 |
Asthenia | 5 (8.1%) | 9 |
Conjunctivitis | 6 (9.7%) | 8 |
Back pain | 7 (11.3%) | 8 |
Cough | 8 (12.9%) | 8 |
Alopecia | 7 (11.3%) | 7 |
Anaemia | 5 (8.1%) | 6 |
Growth of eyelashes | 5 (8.1%) | 5 |
Nausea | 4 (6.5%) | 5 |
Increased blood AP | 5 (8.1%) | 5 |
Weight loss | 4 (6.5%) | 5 |
Headache | 5 (8.1%) | 5 |
Dyspnoea | 5 (8.1%) | 5 |
Decreased appetite | 4 (6.5%) | 4 |